Vladimir Aladinskiy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Vladimir Aladinskiy has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Alex Zhavoronkov
Insilico Medicine
9 shared publications - Alex Aliper
Insilico
8 shared publications - Rim Shayakhmetov
Insilico Medicine Hong Kong Ltd Pak Shek Kok New Territories Hong Kong
5 shared publications - Yan A. Ivanenkov
P. Hertsen Moscow Oncology Research Institute, Moscow, Russian Federation
5 shared publications - Alexander Zhebrak
Insilico Medicine Hong Kong Ltd Pak Shek Kok New Territories Hong Kong
4 shared publications - Daniil Polykovskiy
Insilico Medicine Hong Kong Ltd Pak Shek Kok New Territories Hong Kong
4 shared publications
Latest Publications
- 14 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69  (17) , 20494-20519
Discovery of Highly Potent and Selective, Orally Bioavailable BTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads
Drugs targeting Bruton’s tyrosine kinase (BTK) are recognized as key tools in hematological oncology. The clinical efficacy of BTK inhibitors is limited, however, by the emerging resistance driven by BTK mutations and the severe toxicity attributed to off-target kinase inhibition. PROteolysis TArgeting Chimeras (PROTACs) offer an alternative modality to address these major drawbacks. Herein, we present novel BTK-targeting PROTACs with a high potency against both the wild-type and the mutated BTK. Novel CRBN-binding warheads have been developed to mitigate the off-target protein degradation associated with anchors derived from thalidomide analogues. The linker optimization effort resulted in a series of potent, orally bioavailable BTK-targeting PROTACs without concomitant activity against IKZF1, IKZF3, and GSPT1. The lead compounds ISM-PR25 and ISM-PR44 demonstrate sufficient efficacy in degrading BTK protein in malignant B cells (DC50 = 0.04 and 0.05 nM, respectively) associated with a favorable DMPK profile and a large safety window regarding cell toxicity and effectively degraded BTK in mouse circulating B cells by single-dose oral treatment (3 mg/kg).
- 14 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69  (17) , 20494-20519
Discovery of Highly Potent and Selective, Orally Bioavailable BTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads
Drugs targeting Bruton’s tyrosine kinase (BTK) are recognized as key tools in hematological oncology. The clinical efficacy of BTK inhibitors is limited, however, by the emerging resistance driven by BTK mutations and the severe toxicity attributed to off-target kinase inhibition. PROteolysis TArgeting Chimeras (PROTACs) offer an alternative modality to address these major drawbacks. Herein, we present novel BTK-targeting PROTACs with a high potency against both the wild-type and the mutated BTK. Novel CRBN-binding warheads have been developed to mitigate the off-target protein degradation associated with anchors derived from thalidomide analogues. The linker optimization effort resulted in a series of potent, orally bioavailable BTK-targeting PROTACs without concomitant activity against IKZF1, IKZF3, and GSPT1. The lead compounds ISM-PR25 and ISM-PR44 demonstrate sufficient efficacy in degrading BTK protein in malignant B cells (DC50 = 0.04 and 0.05 nM, respectively) associated with a favorable DMPK profile and a large safety window regarding cell toxicity and effectively degraded BTK in mouse circulating B cells by single-dose oral treatment (3 mg/kg).
- Open Access
The End of Aging Clocks: Training Foundation Models to Reason in Aging and Longevity
The aging clock paradigm has yielded dozens of specialist models that can estimate chronological age or mortality from virtually any biodata type. Yet each such model operates within a fixed modality, relies on a predetermined feature set, and produces limited biological interpretation. Here, we report Longevity-LLM v0.1, a Qwen3-14B model fine-tuned through supervised and reinforcement learning regimes on DNA methylation, proteomics, clinical biomarker, and RNA expression data. Longevity-LLM achieves high ranks in the recently announced Longevity Bench, including such tasks as cancer survival and RNA- or proteome-based age prediction. After reinforcement fine-tuning, the model achieved a 4.34-year MAE in epigenetic age prediction, surpassing the Horvath multi-tissue clock. In addition to age prediction, Longevity-LLM can carry out numerous other tasks, including proteomic profile generation, for which it significantly outperforms all frontier LLMs. These results demonstrate that a single modestly sized LLM can match or replace purpose-built aging clocks across data modalities. This work constitutes an interim report from the initial sprint of our Multi-Modal AI Gym for Science (MMAI), an initiative dedicated to building foundation models for drug discovery and aging research.
Open AccessThe End of Aging Clocks: Training Foundation Models to Reason in Aging and Longevity
The aging clock paradigm has yielded dozens of specialist models that can estimate chronological age or mortality from virtually any biodata type. Yet each such model operates within a fixed modality, relies on a predetermined feature set, and produces limited biological interpretation. Here, we report Longevity-LLM v0.1, a Qwen3-14B model fine-tuned through supervised and reinforcement learning regimes on DNA methylation, proteomics, clinical biomarker, and RNA expression data. Longevity-LLM achieves high ranks in the recently announced Longevity Bench, including such tasks as cancer survival and RNA- or proteome-based age prediction. After reinforcement fine-tuning, the model achieved a 4.34-year MAE in epigenetic age prediction, surpassing the Horvath multi-tissue clock. In addition to age prediction, Longevity-LLM can carry out numerous other tasks, including proteomic profile generation, for which it significantly outperforms all frontier LLMs. These results demonstrate that a single modestly sized LLM can match or replace purpose-built aging clocks across data modalities. This work constitutes an interim report from the initial sprint of our Multi-Modal AI Gym for Science (MMAI), an initiative dedicated to building foundation models for drug discovery and aging research.
- Open Access
- 3 March 2026
- Published by Springer Nature in Scientific Data
- Vol. 13  (1)
Molecular LEGION: incalculably large coverage of chemical space around the NLRP3 target
The exploration and mapping of chemical space remain a central challenge in modern drug discovery. Traditional compound libraries and databases cover only a minute fraction of this space, limiting the discovery of novel, bioactive, and patentable chemotypes. Here, we present a unique dataset containing approximately 110 M molecular structures of potential NLRP3 inhibitors enabled by the LEGION ( Latent Enumeration, Generation, Integration, Optimization, and Navigation ) workflow, which integrates generative AI, AI-guided screening within the Chemistry42 platform and auxiliary cheminformatics tools to enable large-scale exploration of chemical space around specific drug targets. Using the structural data of NLRP3 co-crystals, a clinically relevant target, LEGION combined ligand- and structure-based design strategies, in-house algorithms for 3D pharmacophore-aware scaffold extraction, and distinct library enumeration methods to identify over 34,000 unique scaffolds, which can be multiplied into a dataset of 123B molecular structures within the provided code. The resulting dataset of unprecedented size proved effective for scaffold hopping, chemical space navigation, and supporting intellectual property applications by generating structurally diverse and synthetically accessible structures.
- 3 March 2026
- Published by Springer Nature in Scientific Data
- Vol. 13  (1)
Open AccessMolecular LEGION: incalculably large coverage of chemical space around the NLRP3 target
The exploration and mapping of chemical space remain a central challenge in modern drug discovery. Traditional compound libraries and databases cover only a minute fraction of this space, limiting the discovery of novel, bioactive, and patentable chemotypes. Here, we present a unique dataset containing approximately 110 M molecular structures of potential NLRP3 inhibitors enabled by the LEGION ( Latent Enumeration, Generation, Integration, Optimization, and Navigation ) workflow, which integrates generative AI, AI-guided screening within the Chemistry42 platform and auxiliary cheminformatics tools to enable large-scale exploration of chemical space around specific drug targets. Using the structural data of NLRP3 co-crystals, a clinically relevant target, LEGION combined ligand- and structure-based design strategies, in-house algorithms for 3D pharmacophore-aware scaffold extraction, and distinct library enumeration methods to identify over 34,000 unique scaffolds, which can be multiplied into a dataset of 123B molecular structures within the provided code. The resulting dataset of unprecedented size proved effective for scaffold hopping, chemical space navigation, and supporting intellectual property applications by generating structurally diverse and synthetically accessible structures.
- Open Access
LongevityBench: Are SotA LLMs ready for aging research?
Aging is a core biological process observed in most species and tissues, which is studied with a vast array of technologies. We argue that the abilities of AI systems to emulate aging and to accurately interpret biodata in its context are the key criteria to judge an LLM’s utility in biomedical research. Here, we present LongevityBench — a collection of tasks designed to assess whether foundation models grasp the fundamental principles of aging biology and can use low-level biodata to arrive at phenotype-level conclusions. The benchmark covers a variety of prediction targets including human time-to-death, mutations’ effect on lifespan, and age-dependent omics patterns. It spans all common biodata types used in longevity research: transcriptomes, DNA methylation profiles, proteomes, genomes, clinical blood tests and biometrics, as well as natural language annotations. After ranking state-of-the-art foundation models using LongevityBench, we highlight their weaknesses and outline procedures to maximize their utility in aging research and life sciences.
Open AccessLongevityBench: Are SotA LLMs ready for aging research?
Aging is a core biological process observed in most species and tissues, which is studied with a vast array of technologies. We argue that the abilities of AI systems to emulate aging and to accurately interpret biodata in its context are the key criteria to judge an LLM’s utility in biomedical research. Here, we present LongevityBench — a collection of tasks designed to assess whether foundation models grasp the fundamental principles of aging biology and can use low-level biodata to arrive at phenotype-level conclusions. The benchmark covers a variety of prediction targets including human time-to-death, mutations’ effect on lifespan, and age-dependent omics patterns. It spans all common biodata types used in longevity research: transcriptomes, DNA methylation profiles, proteomes, genomes, clinical blood tests and biometrics, as well as natural language annotations. After ranking state-of-the-art foundation models using LongevityBench, we highlight their weaknesses and outline procedures to maximize their utility in aging research and life sciences.
- Open Access
- 7 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Molecular LEGION: Latent Enumeration, Generation, Integration, Optimization and Navigation. A case study of incalculably large chemical space coverage around the NLRP3 target
The exploration and mapping of chemical space – the vast, multidimensional set of all small organic molecules – remains a central challenge in modern drug discovery. Traditional compound libraries and databases cover only a minute fraction of this space, limiting the discovery of novel, bioactive, and patentable chemotypes. Here, we present LEGION, an advanced workflow that integrates generative AI, AI-guided screening, and state-of-the-art cheminformatics tools within the Chemistry42 platform to enable comprehensive, large-scale exploration of chemical space around specific drug targets. Using NLRP3, a clinically relevant but structurally complex inflammasome protein, as a case study, LEGION combined ligand- and structure-based design strategies, in-house algorithms for 3D pharmacophore-aware scaffold extraction, and distinct library enumeration methods to identify over 34,000 unique scaffolds and generate approximately 110 million molecular structures. Iterative stages of 2D and 3D filtering, including machine learning and structure-based pharmacophore scoring, ensured the binding relevance and structural feasibility of the enumerated compounds. The resulting workflow proved effective for scaffold hopping, navigating unexplored regions of chemical space, and supporting intellectual property applications through the generation of structurally diverse and synthetically tractable structures. This work demonstrates, for the first time, an AI-enabled framework capable of both massive virtual screening and de novo compound generation, specifically tailored for extensive chemical space coverage around a biological target. LEGION establishes a new paradigm for the intelligent, scalable, and practical exploration of chemical space in drug discovery.
- 7 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessMolecular LEGION: Latent Enumeration, Generation, Integration, Optimization and Navigation. A case study of incalculably large chemical space coverage around the NLRP3 target
The exploration and mapping of chemical space – the vast, multidimensional set of all small organic molecules – remains a central challenge in modern drug discovery. Traditional compound libraries and databases cover only a minute fraction of this space, limiting the discovery of novel, bioactive, and patentable chemotypes. Here, we present LEGION, an advanced workflow that integrates generative AI, AI-guided screening, and state-of-the-art cheminformatics tools within the Chemistry42 platform to enable comprehensive, large-scale exploration of chemical space around specific drug targets. Using NLRP3, a clinically relevant but structurally complex inflammasome protein, as a case study, LEGION combined ligand- and structure-based design strategies, in-house algorithms for 3D pharmacophore-aware scaffold extraction, and distinct library enumeration methods to identify over 34,000 unique scaffolds and generate approximately 110 million molecular structures. Iterative stages of 2D and 3D filtering, including machine learning and structure-based pharmacophore scoring, ensured the binding relevance and structural feasibility of the enumerated compounds. The resulting workflow proved effective for scaffold hopping, navigating unexplored regions of chemical space, and supporting intellectual property applications through the generation of structurally diverse and synthetically tractable structures. This work demonstrates, for the first time, an AI-enabled framework capable of both massive virtual screening and de novo compound generation, specifically tailored for extensive chemical space coverage around a biological target. LEGION establishes a new paradigm for the intelligent, scalable, and practical exploration of chemical space in drug discovery.
- 5 June 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16  (7) , 1282-1289
Identification of Novel pan-KRAS Inhibitors via Structure-Based Drug Design, Scaffold Hopping, and Biological Evaluation
KRAS is one of the most frequently mutated oncogenes in human cancers. Discovery of the allosteric binding sites next to the switch II loop triggered the successful development of KRAS-targeting therapeutic agents featuring different modalities. pan-KRAS inhibitors are of particular interest due to the broader scope of clinical indications and potential to overcome certain types of emerging resistance typical of allele-specific KRAS modulators. Herein, we explore the chemical space around MRTX1133, a compound with selectivity toward the KRASG12D variant, aiming to find new chemotypes with the potential to derive a clinical candidate. A series of novel pan-KRAS inhibitors with a potency in the upper nanomolar range have been developed. The inhibitory activity was demonstrated against key oncogenic KRAS mutants and a wild-type protein.
- 5 June 2025
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16  (7) , 1282-1289
Identification of Novel pan-KRAS Inhibitors via Structure-Based Drug Design, Scaffold Hopping, and Biological Evaluation
KRAS is one of the most frequently mutated oncogenes in human cancers. Discovery of the allosteric binding sites next to the switch II loop triggered the successful development of KRAS-targeting therapeutic agents featuring different modalities. pan-KRAS inhibitors are of particular interest due to the broader scope of clinical indications and potential to overcome certain types of emerging resistance typical of allele-specific KRAS modulators. Herein, we explore the chemical space around MRTX1133, a compound with selectivity toward the KRASG12D variant, aiming to find new chemotypes with the potential to derive a clinical candidate. A series of novel pan-KRAS inhibitors with a potency in the upper nanomolar range have been developed. The inhibitory activity was demonstrated against key oncogenic KRAS mutants and a wild-type protein.
- 18 October 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67  (21) , 19121-19142
Discovery of Bis-imidazolecarboxamide Derivatives as Novel, Potent, and Selective TNIK Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis
Traf2- and Nck-interacting kinase (TNIK) has been identified as a promising therapeutic target for the treatment of fibrosis-driven diseases. Utilizing a structure-based drug design workflow, we developed a series of potent TNIK inhibitors that modulate the conformation of the gatekeeper Met105 side chain and access the TNIK back pocket. The lead optimization efforts culminated in the discovery of the recently reported compound 4 (INS018_055), a novel TNIK inhibitor. This molecule demonstrated excellent activity in both enzymatic and cell-based assays, along with high selectivity in a kinome panel. Further, in vitro and in vivo preclinical studies revealed favorable in vitro and in vivo DMPK properties. Results from multiple cell-based and animal models proved that compound 4 exhibits considerable antifibrotic and anti-inflammatory efficacy. Currently, phase II clinical trials of compound 4 are underway for the treatment of idiopathic pulmonary fibrosis (IPF).
- 18 October 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67  (21) , 19121-19142
Discovery of Bis-imidazolecarboxamide Derivatives as Novel, Potent, and Selective TNIK Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis
Traf2- and Nck-interacting kinase (TNIK) has been identified as a promising therapeutic target for the treatment of fibrosis-driven diseases. Utilizing a structure-based drug design workflow, we developed a series of potent TNIK inhibitors that modulate the conformation of the gatekeeper Met105 side chain and access the TNIK back pocket. The lead optimization efforts culminated in the discovery of the recently reported compound 4 (INS018_055), a novel TNIK inhibitor. This molecule demonstrated excellent activity in both enzymatic and cell-based assays, along with high selectivity in a kinome panel. Further, in vitro and in vivo preclinical studies revealed favorable in vitro and in vivo DMPK properties. Results from multiple cell-based and animal models proved that compound 4 exhibits considerable antifibrotic and anti-inflammatory efficacy. Currently, phase II clinical trials of compound 4 are underway for the treatment of idiopathic pulmonary fibrosis (IPF).
- Open Access
- 19 September 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Graph Transformer Foundation Model for modeling ADMET properties
Pre-trained on vast datasets, foundation models demonstrate strong generalization across different tasks, particularly in natural language processing and computer vision. This study explores the potential of applying foundation models to the domain of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) property prediction, a critical task in early-stage drug discovery. We present a Graph Transformer Foundation Model (GTFM) that combines the strengths of graph neural networks (GNNs) and transformer architectures to model molecular graphs. We use self-supervised learning (SSL) to extract useful representations from large unlabeled datasets by predicting masked nodes/edges and the Joint Embedding Predictive Architecture (JEPA). The latter demonstrates superior performance in most tasks by learning robust and predictive features from molecular graphs. The GTFM is benchmarked against classical machine learning models using predefined molecular descriptors. The results demonstrate that the GTFM, especially when employing JEPA, outperforms classical approaches for ADMET property prediction in 8 out of 19 classification and 5 out of 9 regression tasks, being comparable in the rest. This shows foundation models, specifically GTFM, as a promising approach for ADMET modeling, providing a scalable and versatile solution for drug discovery applications.
- 19 September 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessGraph Transformer Foundation Model for modeling ADMET properties
Pre-trained on vast datasets, foundation models demonstrate strong generalization across different tasks, particularly in natural language processing and computer vision. This study explores the potential of applying foundation models to the domain of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) property prediction, a critical task in early-stage drug discovery. We present a Graph Transformer Foundation Model (GTFM) that combines the strengths of graph neural networks (GNNs) and transformer architectures to model molecular graphs. We use self-supervised learning (SSL) to extract useful representations from large unlabeled datasets by predicting masked nodes/edges and the Joint Embedding Predictive Architecture (JEPA). The latter demonstrates superior performance in most tasks by learning robust and predictive features from molecular graphs. The GTFM is benchmarked against classical machine learning models using predefined molecular descriptors. The results demonstrate that the GTFM, especially when employing JEPA, outperforms classical approaches for ADMET property prediction in 8 out of 19 classification and 5 out of 9 regression tasks, being comparable in the rest. This shows foundation models, specifically GTFM, as a promising approach for ADMET modeling, providing a scalable and versatile solution for drug discovery applications.
- 31 July 2020
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63  (17) , 9403-9420
Non-rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza Viruses
4-substituted 2,4-dioxobutanoic acids inhibit influenza virus cap-dependent endonuclease (CEN) activity. Baloxavir marboxil, 4, is approved for treating influenza virus infections. We describe here the synthesis and biological evaluation of active compounds, 5a – 5g, and their precursors (6a, 6b, 6d, and 6e) with flexible bulky hydrophobic groups instead of the rigid polyheterocyclic moieties. In silico docking confirmed the ability of 5a – 5g to bind to the active site of influenza A CEN (PDB code: 6FS6) like baloxavir acid, 3. These novel compounds inhibited polymerase complex activity, inhibited virus replication in cells, prevented death in a lethal influenza A virus mouse challenge model, and dramatically lowered viral lung titers. 5a and 5e potently inhibited different influenza genera in vitro. Precursors 6a and 6d demonstrated impressive mouse oral bioavailability with 6a providing effective in vivo protection. Thus, these novel compounds are potent CEN inhibitors with in vitro and in vivo activity comparable to baloxavir.
- 31 July 2020
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63  (17) , 9403-9420
Non-rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza Viruses
4-substituted 2,4-dioxobutanoic acids inhibit influenza virus cap-dependent endonuclease (CEN) activity. Baloxavir marboxil, 4, is approved for treating influenza virus infections. We describe here the synthesis and biological evaluation of active compounds, 5a – 5g, and their precursors (6a, 6b, 6d, and 6e) with flexible bulky hydrophobic groups instead of the rigid polyheterocyclic moieties. In silico docking confirmed the ability of 5a – 5g to bind to the active site of influenza A CEN (PDB code: 6FS6) like baloxavir acid, 3. These novel compounds inhibited polymerase complex activity, inhibited virus replication in cells, prevented death in a lethal influenza A virus mouse challenge model, and dramatically lowered viral lung titers. 5a and 5e potently inhibited different influenza genera in vitro. Precursors 6a and 6d demonstrated impressive mouse oral bioavailability with 6a providing effective in vivo protection. Thus, these novel compounds are potent CEN inhibitors with in vitro and in vivo activity comparable to baloxavir.
- Open Access
- 19 May 2020
- Published by American Chemical Society (ACS) in ChemRxiv
Potential Non-Covalent SARS-CoV-2 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches and Reviewed by Human Medicinal Chemist in Virtual Reality
One of the most important SARS-CoV-2 protein targets for therapeutics is the 3C-like protease (main protease, Mpro). In our previous work1​we used the first Mpro crystal structure to become available, 6LU7. On February 4, 2020 Insilico Medicine released the first potential novel protease inhibitors designed using a ​de novo,​AI-driven generative chemistry approach. Nearly 100 X-ray structures of Mpro co-crystallized both with covalent and non-covalent ligands have been published since then. Here we utilize the recently published 6W63 crystal structure of Mpro complexed with a non-covalent inhibitor and combined two approaches used in our previous study: ligand-based and crystal structure-based. We published 10 representative structures for potential development with 3D representation in PDB format and welcome medicinal chemists for broad discussion and generated output analysis. The molecules in SDF format and PDB-models for generated protein-ligand complexes are available here and at https://insilico.com/ncov-sprint/.​Medicinal chemistry VR analysis was provided by ​Nanome team and the video of VR session is available at ​https://bit.ly/ncov-vr.​
- 19 May 2020
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessPotential Non-Covalent SARS-CoV-2 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches and Reviewed by Human Medicinal Chemist in Virtual Reality
One of the most important SARS-CoV-2 protein targets for therapeutics is the 3C-like protease (main protease, Mpro). In our previous work1​we used the first Mpro crystal structure to become available, 6LU7. On February 4, 2020 Insilico Medicine released the first potential novel protease inhibitors designed using a ​de novo,​AI-driven generative chemistry approach. Nearly 100 X-ray structures of Mpro co-crystallized both with covalent and non-covalent ligands have been published since then. Here we utilize the recently published 6W63 crystal structure of Mpro complexed with a non-covalent inhibitor and combined two approaches used in our previous study: ligand-based and crystal structure-based. We published 10 representative structures for potential development with 3D representation in PDB format and welcome medicinal chemists for broad discussion and generated output analysis. The molecules in SDF format and PDB-models for generated protein-ligand complexes are available here and at https://insilico.com/ncov-sprint/.​Medicinal chemistry VR analysis was provided by ​Nanome team and the video of VR session is available at ​https://bit.ly/ncov-vr.​